6,134 Shares in Johnson & Johnson (NYSE:JNJ) Purchased by Brady Martz Wealth Solutions LLC

Brady Martz Wealth Solutions LLC acquired a new position in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,134 shares of the company’s stock, valued at approximately $888,000.

Several other large investors have also modified their holdings of JNJ. Providence Capital Advisors LLC lifted its holdings in Johnson & Johnson by 12.4% during the 2nd quarter. Providence Capital Advisors LLC now owns 40,909 shares of the company’s stock valued at $5,979,000 after buying an additional 4,500 shares in the last quarter. Cheviot Value Management LLC raised its stake in shares of Johnson & Johnson by 9.4% during the second quarter. Cheviot Value Management LLC now owns 144,825 shares of the company’s stock valued at $21,168,000 after acquiring an additional 12,488 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of Johnson & Johnson by 506.9% in the second quarter. Marshall Wace LLP now owns 3,884,962 shares of the company’s stock valued at $567,826,000 after purchasing an additional 3,244,862 shares during the period. Distillate Capital Partners LLC purchased a new position in Johnson & Johnson during the 2nd quarter worth $50,013,000. Finally, Gateway Advisory LLC raised its position in Johnson & Johnson by 240.0% during the 2nd quarter. Gateway Advisory LLC now owns 16,780 shares of the company’s stock valued at $2,453,000 after purchasing an additional 11,844 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Wolfe Research initiated coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Royal Bank of Canada raised their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Barclays lowered their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating for the company in a research report on Tuesday. Citigroup cut their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Finally, StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 17th. Eight equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $173.27.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.7 %

NYSE:JNJ opened at $148.10 on Wednesday. The company has a market capitalization of $356.57 billion, a P/E ratio of 21.43, a PEG ratio of 2.39 and a beta of 0.51. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The firm has a fifty day simple moving average of $148.35 and a 200-day simple moving average of $156.11.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.35%. Johnson & Johnson’s payout ratio is presently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.